Naveris develops highly sensitive blood tests, liquid biopsies, that identify viral cancers significantly earlier than is possible with scans or traditional biopsies.

Naveris’ lead product, NavDx®, is a liquid biopsy that uses proprietary technology to enable ultrasensitive surveillance of HPV-related cancer.